Issue link: https://www.e-digitaleditions.com/i/1463386
30 April 2022 Inhalation 31. Azouz W, Chetcuti P, Hosker HSR, Saralaya D, Stephenson J, Chrystyn H. e inhalation char- acteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulmon Deliv. 2015;28(1):35-42. 32. Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients' inhalation maneuvers. Respir Med. 2016,118:65-75. 33. Cidem A, Bradbury P, Traini D, Ong HX. Mod- ifying and integrating in vitro and ex vivo respiratory models for inhalation drug screening. Front Bioeng Biotechnol. 2020;8:article 581995. 34. Pritchard S, McRobbie D. Studies of the human oropharyngeal airspaces using magnetic resonance imaging. II: e use of three-dimensional gated MRI to determine the influence of mouthpiece diameter and resistance of inhalation devices on the oropharyngeal airspace geometry. J Aerosol Med. 2004;17(4):310-324. 35. Delvadia RR, Longest PW, Byron PR. In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug depo- sition variation in normal humans. J Aerosol Med Pulmon Deliv. 2012;25(1):32-40. 36. Ruzycki CA, Martin AR, Finlay WH. An explo- ration of factors affecting in vitro deposition of phar- maceutical aerosols in the Alberta idealized throat. J Aerosol Med Pulmon Deliv. 2019;32(6):405-417. 37. Miller NC. Apparatus and process for aerosol size measurement at varying gas flow rates. US Pat- ent 6,435,004-B1. 2002. 38. Roberts DL, Mitchell JP. Measurement of aero- dynamic particle size distribution of orally inhaled products by cascade impactor: How to let the prod- uct specification drive the quality requirements of the cascade impactor. AAPS PharmSciTech. 2019;20:article 57. 39. Esposito-Festen JE, Ates B, Van Vliet FLM, Ver- braak AFM, de Jongste JC, Tiddens HAWM. Effect of a facemask leak on aerosol delivery from a pMDI- spacer system. J Aerosol Med. 2004;17(1):1-6. Jolyon P. Mitchell, PhD, is President of Jolyon Mitch- ell Inhaler Consulting Services, Inc., London, Canada. Mark W. Nagel, HBSc, is Head of Aerosol Science, Trudell Medical International, London, Canada. Cor- responding Author: Jolyon P. Mitchell, PhD, Jolyon Mitchell Inhaler Consulting Services, Inc., 1154 Saint Anthony Road, London, Ontario, N6H 2R1, Canada, Tel.: +1 519 472-5364, mitchelljolyon@gmail.com. 24. Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Scheuch G. et al. Inhaler competence, barriers to use and recommended solutions. Respir Med. 2013;107:37-46. 25. Mitchell J, Copley M, Sizer Y, Russell T, Solo- mon D. Adapting the Abbreviated Impactor Mea- surement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clin- ical data: A scoping study with the ''Alberta'' ideal- ized throat (AIT) inlet. J Aerosol Med Pulmon Deliv. 2012;25(4):188-197. 26. Finlay W, Zhang Y, Grgic B, Heenan A, Bur- nell P, Matida E, et al.: Solving a major in vitro-in vivo correlation problem: Impactor induction ports. Respir Drug Deliv IX. 2004;1:203-210. 27. Copley M, Mitchell J, Solomon D. Evaluating the Alberta roat: An innovation to support the acquisition of more clinically applicable aerosol aero- dynamic particle size distribution (APSD) data in oral inhaled product (OIP) development. Inhalation. 2011;5(4):12-16. 28. Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am orac Soc. 2004;1:315-320. 29. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930-938. 30. Anderson P. Use of Respimat ® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-259. Please update your email safe senders list We are transitioning to new email addresses. So to ensure you continue to receive Inhalation Magazine and the 123 e-newsletter in your inbox, please keep @cscpublish.com on your safe senders list but add @inhalationmag. com to your safe senders list. anks.